Financial Data and Key Metrics - The company ended Q3 2023 with $26.8 million in cash and no debt, reflecting strong fiscal discipline [14] - Total net sales for Q3 2023 were $19.5 million, up 14% year-over-year, with robust gross margins of 61.4% [25] - Adjusted EBITDA for Q3 2023 was positive $0.5 million, a $1.7 million improvement year-over-year [25] - Year-to-date net sales are up 22%, with adjusted EBITDA of $0.7 million and positive operating cash flow of $6.5 million [25] - E-commerce net revenue increased by 13% year-over-year, driven by marketing initiatives [14] - Watson's contributed $3.1 million in Q3 2023, a 19% increase year-over-year [16] - Niagen ingredient sales decreased by 21% year-over-year, partially offset by increased Tru Niagen sales [27] Business Line Performance - E-commerce remains the largest and most consistent revenue source, with a 13% year-over-year growth [14] - Watson's revenue grew 19% year-over-year, driven by the stacking concept of combining Tru Niagen products [16] - The partnership with iHerb has seen 80% of Tru Niagen sales coming from international consumers [17] - Zesty Paws partnership has led to a second order of Niagen, indicating early success in the pet supplement space [18] - Tru Niagen Pro 1000 mg product line launched, offering a clinical strength dose with proven safety and efficacy [19] Market Performance - The company is focusing on optimizing its website and increasing advertising revenues to drive growth [1] - The partnership with Sinopharm in China continues, with Tru Niagen being featured as the best NR supplement in 2023 [36] - The company is exploring opportunities to expand the stacking concept in other markets [16] - The pet supplement market is growing rapidly, with the global market approaching $2 billion [86] Strategic Direction and Industry Competition - The company is investing in R&D and marketing to position itself for accelerated growth in 2024 and beyond [15][53] - ChromaDex is leveraging its scientific foundation and partnerships to maintain its position as a leader in NAD research [20] - The company is defending its intellectual property, with recent patents protecting NR IP for at least the next decade [23] - The partnership with Nestle Health Science has led to the launch of Solgar cellular nutrition products featuring Niagen [38] Management Commentary on Operating Environment and Future Outlook - Management is confident in setting the stage for further growth opportunities in 2024 and beyond [20] - The company expects to achieve close to breakeven adjusted EBITDA for the full year 2023 [53] - Management highlighted the potential of NAD precursors beyond NR, protected by ChromaDex's IP portfolio [24] - The company is optimistic about the partnership with Zesty Paws and future innovations in the pet supplement space [18] Other Important Information - The company announced two published peer-reviewed clinical studies on Parkinson's disease, with a third study recently completed [22] - ChromaDex continues to defend its achievements and inventions, with a favorable court decision against Elysium Health [43] - The company has extended its 10-year collaboration with W.R. Grace to continue delivering high-quality NAD precursors [69] Q&A Session Summary Question: Revenue Guidance and Seasonality - The company expects a sequential uptick in Q4 2023, driven by seasonally higher Niagen ingredient sales and growth from long-term partners [82] - Management anticipates some seasonality in 2024 but sees building blocks for accelerated growth [83] Question: Expansion into the Pet Supplement Market - The company expects the pet supplement market to go beyond canine, with a global market approaching $2 billion [86] - Zesty Paws has already placed a second order, indicating strong initial performance [86] Question: Watson's Store Expansion - Watson's is currently operating in Hong Kong, Singapore, and Taiwan, with potential for expansion within existing stores [64] - The company is optimistic about further growth but notes that Watson's operates as independently managed businesses [64] Question: Tru Niagen Pro Product Rollout - The Tru Niagen Pro 1000 mg product is targeted at consumers looking to take aging into their own hands, with professional athletes and teams already using it [66][100] - The product has been certified for Sport by NSF International, and the company is leading with MLB and NHL [92] Question: Website Performance and Growth Expectations - The company is seeing improvements in key performance indicators for its website, with a high conversion rate but a need for increased traffic [103] - Management expects significant growth in website sales by Q1 2024 [103] Question: E-commerce Growth and Efficiency - E-commerce growth remains strong, with Amazon performing well, while the website is taking longer to turn around [59] - The company is focusing on scaling its website spend while maintaining targeted efficiencies [52]

Table of Contents General Risks: We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise suf icient capital on favorable terms or at all. Table of Contents Global, market and economic conditions may negatively impact our business, financial condition and share price. As a consumer-focused company, we expect to generate a significant percentage of our future revenue from sales of our Tru Niagen® product. As a result, th ...

Company Participants Conference Call Participants Sean McGowan - ROTH MKM Kendall Knysch Many factors could cause ChromaDex's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These risk factors include those contained in ChromaDex's quarterly reports on Form 10-Q most recently filed with the SEC, including results of operations, financial condition, cash flows, adverse global market and economic conditions on our business. With that ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|---------------------------------------------------------------------------------------| | Delaware | | 26-2940963 | | (State or other jurisdiction of | | (I.R.S. Employer | | incorporation or organization) | | Identification No.) | | 10900 Wilshire Blvd. Suite 600, Los Angeles, | Califor ...

ChromaDex Corporation (NASDAQ:CDXC) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ET Kendall Knysch - Director, Media Relations Brianna Gerber - Chief Financial Officer Conference Call Participants Ram Selvaraju - H.C. Wainwright Sean McGowan - ROTH MKM Jeff Cohen - Ladenburg Thalmann Operator This afternoon, ChromaDex issued a news release announcing the companyÂ's financial results for the first quarter of 2023. If you have not reviewed this information, both are available within the Investor Relat ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|-------|---------------------|-------|---------------------------|------------------------------------------------|-------|---------------------------|-------| | (In thousands except per share data and remaining contractual term) | | Number of Options | | Weighted \nExercise Price | Average \nRemaining Contractual Term (Years) | | Aggregate Intrinsic Value | | | Outs ...

to safely elevate NAD+ levels and the only patented form of nicotinamide riboside (Niagen®) available in the world. Our History (2000-Present) Partnered with Partnered with Launched healthcare practitioner business Announced supply agreement with TRU NIAGEN Singapore New Zealand Commercialized Niagen® (trademarked NR) 2003 2016 2000 2002 2017 2018 2019 2020 2021 2022 Launched Tru Niagen® Beauty with Partnered with Tru Niagen® is the most efficient way to safely elevate NAD+ (1) Related to Nicotinamide Ribos ...

ChromaDex Corporation (NASDAQ:CDXC) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Mitch Pinheiro – Sturdivant Jeff Van Sinderen – B. Riley Ram Selvaraju – H.C. Wainwright Destiny Hance – Ladenburg Thalmann Sean McGowan – Roth MKM Bill Dezellem – Tieton Capital I would now like to turn the conference call over to Tom Shumaker, LifeSci Advisors, Agency IR Counsel for ChromaDex. Please go ahead Mr. Shumaker. Forward-looking statements represent only the company's estimates on the date of this confe ...

Ingredients Segment Analytical Reference Standards and Services Segment According to data from Global Wellness Institute, the global wellness industry market was approximately $4.4 trillion in 2020 amidst the disruptions of COVID-19, which is down from $4.9 trillion in 2019. In 2020, the personal care, beauty and anti-aging market was approximately $960 billion, healthy eating, nutrition and weight loss was approximately $950 billion and traditional and complementary medicine market was approximately $410 b ...

ChromaDex Corporation (NASDAQ:CDXC) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tom Shumaker - Investor Relations Robert Fried - Chief Executive Officer Brianna Gerber - Interim Chief Financial Officer Conference Call Participants Jeff Cohen - Ladenburg Thalmann Sean McGowan - ROTH Capital Jeff Van Sinderen - B. Riley Mitchell Pinheiro - Sturdivant & Company Brian Nagel - Oppenheimer Operator Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corp ...